Healthcare law firm Frier Levitt has analyzed FDA enforcement actions towards “investigation only” peptide distributors. Their summary: the FDA considers an item’s classification based upon its supposed use, not its disclaimers. When Internet sites incorporate dosage guides, reconstitution Recommend